Terms: = Prostate cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Treatment
6 results:
1. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.
Reyes DK; Trock BJ; Tran PT; Pavlovich CP; Deville C; Allaf ME; Greco SC; Song DY; Bivalacqua TJ; Han M; Partin AW; Sartor AO; Rowe SP; Pienta KJ
Med Oncol; 2022 Apr; 39(5):63. PubMed ID: 35478055
[TBL] [Abstract] [Full Text] [Related]
2. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
[TBL] [Abstract] [Full Text] [Related]
3. A 38-gene model comprised of key tet2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.
Kamdar S; Fleshner NE; Bapat B
BMC Cancer; 2020 Oct; 20(1):953. PubMed ID: 33008340
[TBL] [Abstract] [Full Text] [Related]
4. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
[TBL] [Abstract] [Full Text] [Related]
5. Rare Variation in tet2 Is Associated with Clinically Relevant prostate Carcinoma in African Americans.
Koboldt DC; Kanchi KL; Gui B; Larson DE; Fulton RS; Isaacs WB; Kraja A; Borecki IB; Jia L; Wilson RK; Mardis ER; Kibel AS
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1456-1463. PubMed ID: 27486019
[TBL] [Abstract] [Full Text] [Related]
6. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
